TY  - JOUR

T1  - Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

JO  - Blood

PY  - 2019/11/13

AU  - Czerw T

AU  - Malpassuti V

AU  - Iacobelli S

AU  - Koster L

AU  - Kröger N

AU  - Robin M

AU  - Maertens J

AU  - Chevallier P

AU  - Mielke S

AU  - Poire X

AU  - Snowden JA et al

ED  - 

DO  - DOI: 10.1182/blood-2019-123827

PB  - American Society of Hematology

VL  - 134

IS  - Supplement_1

SP  - 3338

EP  - 3338

Y2  - 2024/12/22

ER  -